At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Escitalopram +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers
In Brief
A Phase 4 clinical trial evaluating Escitalopram, Celecoxib, and 1 other intervention for Bipolar Depression. Completed, enrolled 100 participants across 1 site.
Detailed Summary
This project will attempt to enhance and augment the antidepressant efficacy of a commonly used antidepressant in poorly responding bipolar depressed patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Depression
CountriesUnited States
CollaboratorsStanley Medical Research Institute
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedNov 2011
Primary CompletionDec 2017
Study CompletionJan 2018
TodayJul 2026
First PostedNov 24, 2011
Enrollment StartMar 23, 2011
Primary CompletionDec 28, 2017
Study CompletionJan 24, 2018
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 14.6 years ago
Interventions
Escitalopramdrug
Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)
Celecoxibdrug
Celecoxib is a nonsteroidal anti-inflammatory drug
Placebodrug
Placebo is a manufactured capsule with no active ingredient